Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA.
J Med Chem. 2012 Sep 27;55(18):8066-74. doi: 10.1021/jm300917h. Epub 2012 Sep 6.
Histone3-lysine79 (H3K79) methyltransferase DOT1L has been found to be a drug target for acute leukemia with MLL (mixed lineage leukemia) gene translocations. A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM. These compounds also show high selectivity (>4500-fold) over three other histone methyltransferases. Structure-activity relationships (SAR) of these compounds for their inhibitory activities against DOT1L are discussed. Potent DOT1L inhibitors exhibit selective activity against the proliferation of MLL-translocated leukemia cell lines MV4;11 and THP1 with EC(50) values of 4-11 μM. Isothermal titration calorimetry studies showed that two representative inhibitors bind with a high affinity to the DOT1L:nucleosome complex and only compete with the enzyme cofactor SAM (S-adenosyl-L-methionine) but not the substrate nucleosome.
组蛋白 3-赖氨酸 79(H3K79)甲基转移酶 DOT1L 已被发现是具有 MLL(混合谱系白血病)基因易位的急性白血病的药物靶点。共设计和合成了 55 种含腺苷的化合物,其中鉴定出几种具有低至 0.5 nM 的 K(i)值的有效 DOT1L 抑制剂。这些化合物对其他三种组蛋白甲基转移酶也具有高选择性(>4500 倍)。讨论了这些化合物对 DOT1L 抑制活性的结构-活性关系(SAR)。有效的 DOT1L 抑制剂对 MLL 易位白血病细胞系 MV4;11 和 THP1 的增殖表现出选择性活性,EC(50)值为 4-11 μM。等温滴定量热法研究表明,两种代表性抑制剂与 DOT1L:核小体复合物具有高亲和力,仅与酶辅因子 SAM(S-腺苷甲硫氨酸)竞争,而不与底物核小体竞争。